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Anti-apoptosis therapy: A way of treating neural degeneration?
Michael D. Jacobson
Many degenerative diseases involve apoptotic cell
death — can they be treated with apoptosis inhibitors,
while protecting the normal physiological function of
the rescued cells? Reason for optimism comes from a
recent study of mutant flies with an analogue of the
human degenerative disease retinitis pigmentosa.
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Neurodegenerative diseases, including Alzheimer’s and
Parkinson’s, are a major cause of age-related morbidity
and mortality. Current drug treatments are only partially
effective and generally work by improving the function
of the neurons that are still alive, rather than influencing
the underlying mechanisms leading to their death. Over
the past several years, there has been increasing effort on
determining the causes of neuron cell death, with the
aim of developing drugs that will keep the neurons alive
and working.
Cells are thought to die in one of two main ways, necrosis
or apoptosis. Necrotic death is simply what happens when
a cell is so damaged that it literally falls apart: the cell
swells and lyses, and usually elicits an inflammatory
response. Apoptotic cells, by contrast, are typically
shrunken with condensed or fragmented nuclei, and they
are normally cleared rapidly by phagocytosis without any
inflammation and so are often difficult to detect in vivo.
Apoptosis occurs during programmed cell death, a physio-
logically controlled mechanism of cell suicide in animals
that is important for normal development and health [1,2].
Although severely damaged cells often die by necrosis,
the same initial injury in a less severe form usually
induces programmed cell death. Thus, there is some
sense to the idea that inhibiting programmed cell death
may keep damaged cells alive. Indeed, inhibiting pro-
grammed cell death does seem to limit the amount of
neuronal cell death after ischemic brain injury, and pro-
motes functional recovery in animal models of stroke
[3–5]. Such acute injury situations are a major focus of
efforts to find therapeutic uses for inhibitors of pro-
grammed cell death. The case for inhibiting programmed
cell death in degenerative diseases, however, in which the
cellular damage is thought to be sustained, is much less
clear. If a neuron, for example, is too severely damaged to
maintain its physiological functions, rescuing it by block-
ing apoptosis may be useless — or worse, if the rescued
cells behave abnormally.
The death programme has been evolutionarily conserved
in animals, so it is possible to address this issue by
blocking apoptosis in animal models that mimic human
disease. Apoptosis has been studied in the fruitfly
Drosophila melanogaster, for example, where many of the
underlying mechanisms of programmed cell death are the
same as in humans. Although the fruitfly may not seem
like an obvious species in which to test treatments for
neurodegenerative diseases — after all, one fly brain can
fit inside most human ganglia — the advantages of
Drosophila genetics make the species a powerful research
tool. Furthermore, humans and flies are remarkably
similar in terms of their basic cell biology, so flies are a
good species in which to analyse the general biological
correlates of more complex mechanisms in humans.
There are Drosophila mutants, for example, that have a
form of age-related retinal neurodegeneration that is very
similar to retinitis pigmentosa, a leading cause of blind-
ness in humans. Retinitis pigmentosa is an inherited
degenerative disease involving the loss of rod photore-
ceptor cells, and can be caused by any one of several
mutations affecting proteins expressed in rod cells that
are involved in signal transduction or protein transport.
Similar mutations in humans and fruitflies are known that
produce analogous phenotypes. Mutations in the
rhodopsin gene, which encodes the light-receptor protein
in rods, are the most common, accounting for about 30%
of human autosomal dominant retinitis pigmentosa.
Equivalent mutations in the Drosophila rhodopsin gene
also cause age-related retinal degeneration [6], suggest-
ing that, despite the differences in photoreceptor physi-
ology, these mutations cause photoreceptor death by a
common mechanism.
In rodent models of retinitis pigmentosa, the rod deaths
are apoptotic [7–9], suggesting that the final common
mechanism of these cell deaths in mammals, and possibly
flies, is programmed cell death. The fact that such deaths
are apoptotic is important: the molecular basis for pro-
grammed cell death is rapidly becoming understood, and
there are several ways to inhibit it. The most immediately
promising method is by blocking the activity of a family of
proteases that mediate programmed cell death, the cas-
pases. These are aspartate-directed cysteine proteases that
seem to be essential for programmed cell death in animals.
Synthesized as inactive zymogens, they are activated by
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cleavage at specific aspartic acids. Once activated, they
activate other caspases in a protease cascade, eventually
leading to the cleavage of specific target proteins and pro-
grammed cell death.
Davidson and Steller [10] have provided elegant proof
that blocking caspases, and thereby programmed cell
death, can rescue physiological function in fruitflies with
mutations causing retinal degeneration. One such muta-
tion, ninaERH27, is a dominant rhodopsin mutation — a
cysteine for tyrosine substitution at residue 200 — with a
human equivalent that causes severe retinitis pigmentosa.
Retinal degeneration in these flies begins after about
three weeks of age. The other retinal degeneration mutant
tested, rdgC306, is caused by a deletion of a serine/threo-
nine phosphatase that dephosphorylates light-activated
rhodopsin. In homozygous rdgC306 mutant flies, retinal
degeneration begins after two days of exposure to constant
light (dark-reared flies do not show a retinal degeneration
phenotype). Although there is no known exact human
analogue of this mutation, a mutation near the phosphory-
lation site of human rhodopsin causes autosomal dominant
retinitis pigmentosa. In both types of mutant fly, the
photoreceptor death was clearly apoptotic. 
Davidson and Steller [10] blocked these cell deaths by
making use of a broad-spectrum caspase-inhibitory
protein, baculovirus p35, which has been shown to inhibit
apoptosis in insects, nematodes and mammalian cells
[11–14] (Figure 1). Flies that were engineered to express
p35 protein specifically in the eyes were crossed with the
retinal degeneration (rd) mutant flies, and the rd/p35 off-
spring of these crosses were then compared with corre-
sponding wild-type and rd mutant flies for signs of
photoreceptor degeneration, apoptosis and visual function.
The rd/p35 flies, unlike their corresponding rd relatives,
showed no signs of retinal degeneration, and apoptosis was
completely blocked. Most importantly, the visual function
in rd/p35 flies was retained throughout their life.
The most obvious implication is that blocking
programmed cell death with caspase inhibitors may be a
therapeutically useful strategy for slowing or preventing
loss of neural function in neurodegenerative diseases.
Although this interpretation seems to be relatively
straightforward, it is important to consider some of the
complexities of caspases in mammals. The first is their
heterogeneity. There are at least 14 caspases in humans,
and they can be grouped into three main functional
classes [15]: the interleukin-1β converting enzyme (ICE)-
like caspases, which are involved in processing pro-
inflammatory cytokines; the ‘upstream’ signalling
caspases that cleave and activate downstream caspases;
and the ‘downstream’ effector caspases, such as CPP32
(caspase-3), involved in the execution phase of the death
programme. There are also multiple caspases in
Drosophila — two have been reported so far — although it
is not clear whether they fall into all the same functional
classes as in mammals.
This functional diversity complicates the interpretation of
experiments with caspase inhibitors. Some caspases are at
the head of a signalling pathway that leads to activation of
downstream caspases and programmed cell death. FLICE
(caspase-8), for example, is involved in directly mediating
the activation of death-signalling receptors, such as CD95
(Fas/Apo-1) and tumour necrosis factor receptor-1
(TNF-R1). Inhibiting this caspase blocks most down-
stream signalling events that result in programmed cell
death. By contrast, inhibiting ICE-like caspases blocks
production of certain inflammatory cytokines, but gener-
ally does not block programmed cell death directly. Inhi-
bition of caspase-dependent cytokines may have the
indirect effect of inhibiting programmed cell death,
however, because some of the cytokines stimulate stress-
signalling pathways. For example, blocking cytokine pro-
duction or function — by blocking the receptors — has
been observed to inhibit programmed cell death in vitro
and in vivo. In mice, inhibiting interleukin-1 (IL-1) pro-
duction and ICE activity, either by expression of domi-
nant-negative proteins or by injecting peptide caspase
inhibitors, confers resistance to cerebral ischemia
[4,16,17]. Caspase-activated cytokines may thus be 
Figure 1
The putative stress-activated cell-death pathway in photoreceptor
cells. The combination of light and altered protein — such as mutant
rhodopsin — triggers signals that lead to caspase activation and
apoptosis. The caspase inhibitor p35 blocks this apoptosis;
surprisingly, p35 also maintains normal cell physiology [10]. Survival
factors can also inhibit retinal degeneration. Little is known about the
apoptosis-inducing pathways, upstream of caspase activation, that are
trigged by mutant or altered proteins.
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important in triggering programmed cell death in some
circumstances, such as after a stroke.
The differences between cytokine-producing, upstream
and downstream caspases may in fact be more blurred
than this distinction implies — CPP32, for example,
which behaves most clearly as a downstream caspase, has
been found to process a cytokine [18]. This complexity
will pose a challenge to understanding the role of caspases
in chronic degenerative diseases, where the role of pro-
grammed cell death is not clear. In amyotrophic lateral
sclerosis (ALS), for example, inhibiting ICE-like caspases
in an animal model of the disease (by using a dominant-
negative form of ICE) seems to slow the progression of
motorneuron loss and paralysis that occurs after disease
onset [19]. It is not known, however, whether this effect is
a result of inhibiting cytokine production, blocking pro-
grammed cell death or both. One message from these
findings is that therapies should target stress-signalling
pathways that are upstream of the death programme.
Caspase inhibitors can affect both pathways.
Another issue is whether blocking caspases can keep most
cells alive even if apoptosis is prevented. This complica-
tion is suggested by some observations in cell culture in
which peptide caspase inhibitors, although effective in
blocking apoptosis induced by an activated oncogene or
by changing culture conditions, did not rescue the cells
from eventual death [20,21]. One possibility is that some
death-signalling events upstream of caspases, such as
mitochondrial pore-opening, eventually kill the cell
despite the caspase blockade. Alternatively, the peptide
inhibitors might not be completely effective in some cells
and conditions, perhaps because they are metabolised dif-
ferently. Nevertheless, even if one assumes a perfectly
effective caspase inhibitor, the problem remains of
whether inhibiting caspases can be an effective treatment
over many years, as would be required for an anti-degen-
erative drug in humans. In fruitflies, normal cell function
needs to be maintained for mere weeks.
Despite all of these problems in extrapolating to humans, it
remains a big surprise that the rd/p35 flies were able to see
throughout their lives, and therefore that the photorecep-
tor cells were completely normal. Whatever the complexi-
ties of caspase biochemistry or cell pathology, it is
encouraging that blocking caspases rescued retinal func-
tion at all, especially as the underlying cell damage caused
by the rd mutation was unaffected. One possible explana-
tion for these cells’ ability to function is that they were not
actually as severely damaged as one might assume.
Although cells can respond to stressful stimuli by activating
the death programme, the insult can be minor. DNA dam-
aging treatments, for example, can activate the p53 protein
— a DNA-damage detector that can induce apoptosis or
cell-cycle arrest — with as little as one DNA double-strand
break per cell [22]. Analogously, a relatively subtle muta-
tion affecting an abundant protein might nevertheless
trigger programmed cell death in a photoreceptor, possibly
by activating a signalling pathway that responds to mis-
folded, mistargeted or aggregated proteins. Indeed, there is
support for the idea that aberrant protein aggregation
might be important in neurodegenerative disease [23].
Complete functional rescue of every cell may not be
needed, however, if some of the deaths are not cell-
autonomous [24]. In rd fruitflies, only six of the eight
photoreceptor cells (R1–6) in every ommatidium express
the mutant form of rhodopsin, and these cells die first.
The other two photoreceptor cells (R7 and R8) express a
different form of rhodopsin and are not directly affected,
but they die shortly after the R1–6 cells, suggesting that
they require signals from the R1–6 cells to survive. The
equivalent human disease is remarkably similar: in retini-
tis pigmentosa, the rods are directly affected and die first,
producing night blindness. This does not result in daylight
blindness, however, as the colour-sensitive cone cells
remain. Yet the cones, although not directly affected by
the disease mutation, eventually die, leading to complete
blindness. The simplest explanation is that the rods
provide survival signals to the cones. Protecting the rods
may thus at least have the indirect benefit of keeping the
cones alive, thereby preventing total blindness, clearly
much more debilitating than night blindness. The same
argument applies to other neurodegenerative diseases, as
it is generally a subpopulation of neurons that is initially
affected; keeping damaged cells alive, even if they are not
fully functional, may support the survival of neighbouring
undamaged cells that depend on them for survival signals,
thus maintaining the integrity of the overall tissue.
The main lesson from the Drosophila studies is that an
apoptosis inhibitor can prevent a neurodegenerative
disease. One may therefore be forgiven for being opti-
mistic about the prospects for treatment of human neu-
rodegeneration. Although effective treatments will take
some time to develop, it is worth keeping in mind that
most of the current research in apoptosis involves a rela-
tively limited number of reagents directed against a few
components of the death programme. As we understand
the mechanisms of cell death more fully, and as more
reagents that affect various cell death pathways become
widely available, the full potential for this approach will
become more apparent. Preventing blindness in fruitflies
may not seem like a huge step, but it is the first.
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